NCT05856864

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

Detailed description

An open, single-arm, single-centre,Phase II clinical study evaluating Cadonilimab in combination with Ramucirumab for the treatment of advanced hepatocellular carcinoma that has failed at systemic therapy

Conditions

• Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Interventions

Type	Name	Description
DRUG	Cadonilimab Injection	Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
DRUG	Ramucirumab Injection	Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,

Timeline

• Start date: 2024-06-01
• Primary completion: 2024-07-01
• Completion: 2025-05-01
• First posted: 2023-05-12
• Last updated: 2024-04-15

Locations

1 site across 1 country: China